UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June, 2022.

Commission File Number: 001-40627

SOPHiA GENETICS SA
(Exact name of registrant as specified in its charter)

Rue du Centre 172
CH-1025 Saint-Sulpice
Switzerland
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SOPHiA GENETICS SA

Date: June 15, 2022

By: /s/ Daan van Well
Name: Daan van Well
Title: Chief Legal Officer

EXHIBIT INDEX

<table>
<thead>
<tr>
<th>Exhibit No.</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>99.1</td>
<td>Press release dated June 15, 2022</td>
</tr>
<tr>
<td>99.2</td>
<td>ESG Impact Summary June 2022</td>
</tr>
</tbody>
</table>
SOPHiA GENETICS Publishes Environmental, Social and Governance Impact Summary

BOSTON, United States and LAUSANNE, Switzerland, June 15, 2022 — SOPHiA GENETICS SA (Nasdaq: SOPH) (“the Company”), today announced that the Company has published its first Environmental, Social and Governance Impact Summary (“ESG Impact Summary”). The ESG Impact Summary highlights the Company’s policies, ongoing practices, and recent initiatives across a range of areas including innovation and access, protecting patient data, empowering its people, as well as other key priority areas. The ESG Impact Summary is available on SOPHiAGENETICS.COM, in the Investor Relations section.

“We are thrilled to be taking the first steps in SOPHiA GENETICS’ ESG journey. We place patient care at the heart of all our decisions. Our success is deeply rooted in our core values and the positive impact we have in the ESG areas across all levels of the organization. This is critical to our mission of creating a wiser and more sustainable healthcare system,” said Dr. Jurgi Camblong, Co-Founder and CEO at SOPHiA GENETICS.

About SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by more than 790 hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn and Instagram. Where others see data, we see answers.

Investor Contact
Jennifer Pottage
Head of Investor Relations
Jpottage@sophiagenetics.com

Media Contact
Don Granese
Public Relations
Dgranese@sophiagenetics.com
ESG Impact Summary
June 2022

The information contained in this document is accurate only as of its date. In addition, this document contains statements that constitute forward-looking statements, which are subject to risks and uncertainties, including those described in our filings with the U.S. Securities and Exchange Commission. We do not have any obligation or undertaking to update these forward-looking statements, unless required to do so by applicable law.
Foreword by Dr. Jurgi Camblong, Co-Founder and CEO

When founding the company with Pierre and Lars, in 2011, our goal was to create a tech company whose impact would significantly improve patient care. We believe our corporate DNA, rooted in quality, precision, and robustness is the key to our success and a promise of hope for millions worldwide.

We are convinced that the long-term success of SOPHIA GENETICS is deeply connected to our ability to create value for all stakeholders. Having a positive impact across all levels of our organization is critical to pursue our mission to build a more sustainable global healthcare system.

Of course, this requires complying with all applicable laws and regulations, but we must go further and ensure that every decision we make aims to create shared value between our investors, our employees, the healthcare institutions we work with, and the patients of our customers.

With this in mind, we’ve compiled this Environmental, Social and Governance (ESG) Impact Summary highlighting the key areas in which we create value every day. As the first step of our ESG journey, this report marks our commitment to transparently managing and reporting the impacts of our activities. We look forward to sharing our progress in the years to come.

Dr. Jurgi Camblong, Co-Founder & CEO
**Mission**

**Performance Indicators & Discussion**

**Innovation & Access**

**Facilitate clinical research**
Leverage data-driven insights to advance research on new treatments

As of December 31, 2021, our platform has been used in clinical trials and research projects in more than 300 peer-reviewed publications. These papers demonstrate how our solutions help drive insights and support scientists to enhance and accelerate disease discoveries. We believe our technologies have the potential to revolutionize patient care across a multitude of health conditions.

**Enable data sharing**
Connecting institutions and enabling them to draw actionable results from the network effect inherent to our platform is key to advancing patient care

As of December 31, 2021, we serve more than 70 hospitals, laboratories and biopharma customers in more than 70 countries.

**Promote Access to Data-Driven Medicine**
Improve patient care on a global scale

We are proud to bring data-driven medicine to those who need it the most, across oncology, rare and inherited diseases, infectious diseases, cardiology, neurology, and other disease areas. Our solution has supported the analysis of 1.5M genomic profiles and more than 2.4M analyses as of December 31, 2021, leveraging our unique multi-modal capabilities.

**Protecting Patient Data**
Facilitate insight-sharing while protecting patient information

**Strong information governance**
Build data protection and transparency into our corporate structure

We take the privacy of individuals seriously and pledge to respect the confidentiality of personal data and protected health information. We remain transparent, and strive to keep all data safe. Following our Code of Business Conduct and applicable data protection laws and regulations, for this purpose, we have implemented a global compliance plan, appointing a Data Protection Officer, a HIPAA Compliance Officer, creating a Data Protection Committee, and an Information Security Committee.

**Embedded procedures**
Develop integrated data protection mechanisms

We have prepared and implemented global policies and procedures, including a data protection policy, a retention procedure, a data breach response plan, and standard operating procedures to address data subjects requests. We have guidelines in place and conduct training of relevant personnel on data protection to ensure the security of processing activities. These policies and procedures are reviewed and updated to ensure optimal patient privacy.

**Secure technology**
Ensure we are at the cutting-edge of software technology for patient data protection

Our data architecture ensures the pseudonymization of the personal data processed. We take steps to ensure that personal data in our control is protected from misuse or unauthorized destruction, editing, alteration, disclosure, acquisition or access. To this effect and to ensure an appropriate level of security, we have implemented ISO/IEC 27001:2013 standards with respect to technical and physical security.

Our HIPAA standards set forth in the Security Rule are audited annually through a Risk Assessment performed by our Compliance and Information Security Department. We have administrative, technical, and physical security measures to safeguard the protected health information we receive.

**Empowering our People**
Providing our people with the necessary tools to achieve our goals

**Engaged employees**
Achieve best-in-class employee engagement

We actively assess employee engagement with surveys that include quantitative and qualitative information. The results from the surveys are interpreted and used by our people management organization to focus on improving areas of concern and reinforcing areas of strength. We are pleased that 97% of our workforce participated in the 2021 survey and responses indicate strong satisfaction with management support, equality, and peer relationships.

**Personal development**
Enable our people to expand their knowledge, skills, and advance their careers

As part of our effort to continuously motivate and provide professional development for our employees, we support talent reviews and have created career ladders for all departments. In the past year, we have offered more than 63 new opportunities, with promotions, 82% of which were first-time promotions. We also provided training through our Learning@SOPHIA program, which enabled our people to complete 7,000 training hours.

**Employee diversity**
Nurture a diverse and inclusive workforce

We create work environments that preserve and value individuality and diversity. We believe that diversity in our workforce boosts employee engagement and creates an innovative, dynamic, and productive culture. As of December 31, 2021, we had 518 employees globally, and our worldwide gender distribution of men/women/un disclosed was 58%/39%/3%, respectively. Diversity at SOPHIA GENETICS is overseen by our Board’s nomination and corporate governance committee.

---

Not for reporting purposes and only to be referred to in the full version.
Being a responsible corporate citizen

**Ethics**

*Rooting business decisions in a true sense of integrity*

We strive to place patients' care at the heart of all our decisions and have elaborated our Code of Business Conduct with this in mind. We have firm rules guiding our interactions with healthcare professionals, measures and policies to prevent corruption, fraud, conflict of interest, anti-competitive behavior, and insider trading. We stand strongly against any form of discrimination, and workplace harassment issues are dealt with firmly according to our Whistleblowing procedure and speak-up tool, marking our commitment to being a safe and inclusive workplace. To ensure our partners also apply high ethical standards, we have a third-party risk management program which includes a due diligence process for new partnerships. We also review partners according to business conduct standards.

**Governance**

*Leading by example*

SOPHIA GENETICS' Board of Directors set high standards for our employees, officers, and directors. The importance of sound corporate governance is implicit to our values of quality, precision, and robustness. It is the duty of the Board of Directors to serve as trustees for our shareholders and to oversee the management of the company's business. As of December 31, 2021, six out of seven of our Board members are independent directors based on Nasdaq's independence standards, including our Chair. As of December 31, 2021, our Board committees, namely the Audit Committee, the Compensation Committee, and the Nomination & Corporate Governance Committee, are each composed of three members - all independent directors - and respond to their respective charters. As part of our commitment to expanding our ESG focus, we have assigned the responsibility for ESG oversight to our Board's Nomination and Corporate Governance Committee.

Not for reporting purposes and only to be referred to in the full version.
In building this report, alongside conducting our own assessment of the key material topics for the company, we referred to the SASB Industry-Specific Materiality Map for both the Software & IT Services and Biotechnology & Pharmaceuticals industries. In the table below, we have highlighted the main points of relevance to SOPHiA GENETICS’ activities at this stage in the company’s development.

<table>
<thead>
<tr>
<th>Industry</th>
<th>Topic</th>
<th>SASB Code</th>
<th>Accounting Metrics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Environmental Footprint of Hardware Infrastructure</td>
<td>TCG-110a.1</td>
<td>Our current assessment is that our primary environmental impact comes from our server usage. On this matter, we benefit from having our servers hosted by Microsoft. We plan to further develop our environmental reporting capabilities in the coming year.</td>
<td></td>
</tr>
</tbody>
</table>
| Software & IT services            | Data Privacy & Freedom of Expression       | TCS-120a.1 | SOPHiA GENETICS implemented a global compliance plan in accordance with applicable laws and regulations, including:  
- The appointment of a Data Protection Officer;  
- The appointment of an HR/Compliance Officer;  
- The creation of a Data Protection Committee and Information Security Committee, in which both the Data Protection Officer and the Information Security Director are the relevant managers;  
- The preparation of processes and guidelines;  
- Training of appropriate personnel on data protection; and  
- The security of processing activities. |
|                                    |                                            | TCS-120a.2 | SOPHiA GENETICS is processing 99% of its used data for secondary purposes. Only few exceptions for specific projects are expressly excluded |
|                                    |                                            | TCS-120a.3 | No legal proceedings associated with user privacy have been initiated against SOPHiA GENETICS |
|                                    |                                            | TCS-120a.4 | No requests for user information from government or law enforcement agencies have been received:  
1. 0  
2. 0  
3. 0% - NA |
|                                    |                                            | TCS-310a.3 | Percentage of gender group representation for: (1) management (Director & above), (2) technical staff, Information Technology and Data Science, and (3) all other employees (below Director & non-IT and DS):  
1. 62% male, 38% female, 0% did not disclose  
2. 76% male, 24% female, 0% did not disclose  
3. 43% male, 56% female, 4% did not disclose |
| Bio-technology & Pharmaceuticals   | Business Ethics                            | HC-BP-310a.1 | No legal proceedings associated with corruption and bribery have been initiated against SOPHiA GENETICS |
|                                    |                                            | HC-BP-310a.2 | As part of our commitment to the patients of our customers, our Code of Business Conduct defines how we interact with Healthcare professionals. We build connected relationships with our customers and more broadly with the healthcare community to offer data and analytics services linked notably to genomic and imaging solutions. We must never bribe or offer other forms of compensation to gain business view. We do not have an anti-bribery policy. We should act in the same way as courtesies in other sectors may not be appropriate when interacting with healthcare professionals. Our interactions with healthcare professionals are governed by internal ethics based on U.S. E.U., Swiss standards and local requirements when stricter. See our Code of Business Conduct for more information. |

Not for reporting purposes and only to be referred to in the full version.